eventscribe

The eventScribe Educational Program Planner system gives you access to information on sessions, special events, and the conference venue. Take a look at hotel maps to familiarize yourself with the venue, read biographies of our plenary speakers, and download handouts and resources for your sessions.

close this panel

SUBMIT FEEDBACKfeedback icon

Please enter any improvements, suggestions, or comments for the JSM Proceedings to make your conference experience the best it can be.

Comments


close this panel
support

Technical Support


Phone: (410) 638-9239

Fax: (410) 638-6108

GoToMeeting: Meet Now!

Web: www.CadmiumCD.com

Submit Support Ticket


close this panel
‹‹ Go Back

Sylvia Julien

IPSEN Innovation SAS



‹‹ Go Back

Emmanuel Pham

IPSEN Innovation SAS



‹‹ Go Back

Philippe Saint-Pierre

Universite de Toulouse



‹‹ Go Back

Nicolas Savy

Universite de Toulouse



‹‹ Go Back

Stephanie Savy

Estrials



‹‹ Go Back

Please enter your access key

The asset you are trying to access is locked for premium users. Please enter your access key to unlock.


Email This Presentation:

From:

To:

Subject:

Body:

←Back IconGems-Print

172 – Quantitative Decision Making in Clinical Trials

In Silico Clinical Trials: A Way to Improve Drug Development?

Sponsor: Biopharmaceutical Section
Keywords: Clinical trials, Simulation, Methodology, Agent-based model

Sylvia Julien

IPSEN Innovation SAS

Emmanuel Pham

IPSEN Innovation SAS

Philippe Saint-Pierre

Universite de Toulouse

Nicolas Savy

Universite de Toulouse

Stephanie Savy

Estrials

Many clinical trials are negative or inconclusive. Thomas Burns (Clinical Development Success Rates 2006-2015, 2016) estimates to 42 % the proportion of Phase III trials which fails to meet the primary objective. The causes of such failure are numerous. Obviously, there is the lack of effect of the treatment under study, a cause which cannot be anticipated. But there are other causes related to trial design and trial operation that can be avoided or at least tested by means of simulation studies. The aim of In Silico Clinical Trials (ISCT) is to test the feasibility of an experimental design and to evaluate its sensitivity to a modification of the design parameters. By this way, one can optimize the trial design by anticipate what can happen during the trial. The purpose of this presentation is to outline what an ISCT may be and to focus on the methodological pillars of this approach (clarity / parsimony / completeness). Issues on the development of ISCT will also be discussed.

"eventScribe", the eventScribe logo, "CadmiumCD", and the CadmiumCD logo are trademarks of CadmiumCD LLC, and may not be copied, imitated or used, in whole or in part, without prior written permission from CadmiumCD. The appearance of these proceedings, customized graphics that are unique to these proceedings, and customized scripts are the service mark, trademark and/or trade dress of CadmiumCD and may not be copied, imitated or used, in whole or in part, without prior written notification. All other trademarks, slogans, company names or logos are the property of their respective owners. Reference to any products, services, processes or other information, by trade name, trademark, manufacturer, owner, or otherwise does not constitute or imply endorsement, sponsorship, or recommendation thereof by CadmiumCD.

As a user you may provide CadmiumCD with feedback. Any ideas or suggestions you provide through any feedback mechanisms on these proceedings may be used by CadmiumCD, at our sole discretion, including future modifications to the eventScribe product. You hereby grant to CadmiumCD and our assigns a perpetual, worldwide, fully transferable, sublicensable, irrevocable, royalty free license to use, reproduce, modify, create derivative works from, distribute, and display the feedback in any manner and for any purpose.

© 2019 CadmiumCD